DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.42
-0.35 (-5.17%)
At close: Apr 1, 2026, 4:00 PM EDT
6.52
+0.10 (1.56%)
After-hours: Apr 1, 2026, 5:01 PM EDT
DiaMedica Therapeutics Employees
As of December 31, 2024, DiaMedica Therapeutics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,170,214
Market Cap
345.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | 11 | 2 | 22.22% | 10 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Ginkgo Bioworks Holdings | 485 |
| Invivyd | 122 |
| Enanta Pharmaceuticals | 120 |
| Armata Pharmaceuticals | 60 |
| Candel Therapeutics | 55 |
| X4 Pharmaceuticals | 45 |
| Benitec Biopharma | 19 |
DMAC News
- 1 day ago - DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - Business Wire
- 2 days ago - Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
- 9 days ago - DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - Business Wire
- 27 days ago - DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - Business Wire
- 5 weeks ago - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
- 2 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire